Abstract
Background: Conjunctivitis is common in patients with atopic dermatitis (AD) in general and a commonly reported adverse event in AD clinical trials with dupilumab. Objective: To survey opinions and experience about conjunctivitis occurring in AD, including those during dupilumab treatment in a group of AD experts from the International Eczema Council (IEC). Methods: Electronic survey and in-person discussion of management strategies. Results: Forty-six (53.5%) IEC members from 19 countries responded to the survey. Consensus was reached for several statements regarding diagnostic workup, referral and treatment. IEC members suggest that patients with AD should (i) routinely be asked about ocular complaints or symptoms, (ii) obtain information about the potential for conjunctivitis before starting dupilumab therapy and (iii) if indicated, be treated with dupilumab despite previous or current conjunctivitis. In cases of new-onset conjunctivitis, there was consensus that dupilumab treatment should be continued when possible, with appropriate referral to an ophthalmologist. Limitations: The study relies on expert opinion from dermatologists. Responses from few dermatologists without dupilumab access were not excluded from the survey. Conclusion: The IEC recommends that dermatologists address conjunctivitis in patients with AD, especially during treatment with dupilumab.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1224-1231 |
| Number of pages | 8 |
| Journal | Journal of the European Academy of Dermatology and Venereology |
| Volume | 33 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 2019 |
Funding
Dr. Thyssen has attended advisory boards for Roche, Eli Lilly and Sanofi Genzyme and received speaker honorarium from LEO Pharma and Sanofi Genzyme. Dr. de Bruin-Weller M has been a principal investigator, advisory board member and consultant for Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme and a principal investigator, advisory board member for AbbVie. Dr. Paller has been a principal investigator for AbbVie, Anaptysbio, Eli Lilly, Galderma, Incyte, Leo, Janssen, Novartis and Regeneron, and a consultant for AbbVie, Amgen, Asana, Dermavant, Dermira, Galderma, Eli Lilly, Forte, Leo, MatriSys, Menlo, MorphoSys/Galapagos, Novartis, Pfizer, Regeneron and Sanofi. Dr. Leshem has been a principal investigator, consultant and/or advisory board member for and/or received honoraria from AbbVie Inc., Sanofi and Regeneron Pharmaceuticals Inc., Pfizer, Dexcel Pharma, Genentech and Eli Lilly. Dr Vestergaard has been a investigator, speaker or consultant for Novartis, AbbVie, Sanofi, Leo Pharma and Eli Lilly. Dr. Deleuran has been a principal investigator, speaker, advisory board member and/or consultant for LEO Pharma, Lilly, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, MorphoSys-Galapagos, Pierre Fabre and MEDA. Dr. Drucker has served as a investigator and has received research funding from Sanofi and Regeneron and has been a consultant for Sanofi, RTI Health Solutions, Eczema Society of Canada and Canadian Agency for Drugs and Technology in Health. He has received honoraria from Prime Inc, Spire Learning, CME Outfitters and Eczema Society of Canada. His institution has received educational grants from Sanofi. Dr. Fo€lster-Holst has been a investigator, speaker or consultant for Astellas, Almirall Hermal, Beiersdorf, Johnson & Johnson, La Roche-Posay, LEO Pharma, Neubourg GmbH, Novartis, Pierre Fabre, Procter & Gamble and Regeneron Pharmaceuticals. Dr Traidl-Hoffmann has been a investigator, speaker or consultant for Novartis, Lilly, Regeneron Pharmaceuticals, Sanofi Genzyme and Sebapharma. Dr. Kilian Eyerich has been a principal investigator, advisory board member or consultant for AbbVie, Almirall, Berlin-Chemie, Hexal, Janssen, Leo, Lilly, Novartis and Sanofi. Dr Alain Ta€ıeb has been a consultant or investigator for Pierre Fabre, Galderma, Novartis, Johnson and Johnson and Sanofi. Dr Su has been a principal investigator, consultant or advisory board member for Amgen, AbbVie, Eli Lilly, Janssen, Meda, Novartis, Pfizer, Pierre Fabre and Sanofi. Dr. Bieber has been a principal investigator, advisory board member or consultant for Regeneron, Sanofi, GSK, Celgene, AbbVie, AnaptysBio, MedImmune, Chugai, Pierre Fabre, Novartis, Asana Biosciences, LEO, Galapagos/MorphoSys, BioVersys, Galderma, Kymab, Glenmark, Astellas, Daiichi-Sankyo, Lilly, Pfizer, MenloTx, Dermavant and Almirall. Dr Michael J. Cork is a investigator and consultant for Regeneron, Sanofi Genzyme, Pfizer, Leo, Galapagos, Novartis, Boots, L’Oreal, Dermavant, Menlo, Reckitt Benckiser, Oxagen, Johnson & Johnson, Hyphens, Astellas, AbbVie, Galderma and Procter & Gamble. Dr. Eichenfield has been a principal investigator, consultant or advisory board member for Amgen, Dermavant, Dermira, Eli Lilly, Forte, Galderma, Leo, MatriSys, Menlo, MorphoSys, Novartis, Ortho Dermatologics, Pfizer, Pierre Fabre and Regeneron/Sanofi. Dr Guttman-Yassky is an employee of Mount Sinai and has received research funds (grants paid to the institution) from AbbVie, Celgene, Eli Lilly, Janssen, MedImmune/Astra Zeneca, Novartis, Pfizer, Regeneron, Vitae, Glenmark, Galderma, Asana, Innovaderm, Dermira, UCB, Kiniksa and Novan. EGY is also a consultant for Sanofi Aventis, Regeneron, Stiefel/GlaxoSmithKline, MedImmune, Celgene, AnaptysBio, Dermira, Galderma, Glenmark, Novartis, Pfizer, Vitae, Leo Pharma, AbbVie, Eli Lilly, Kyowa Kirin, Mitsubishi Tanabe, Asana Biosciences, Promius, Kiniksa, Novan and Evelo biosciences. Dr. Wollenberg has been a principal investigator, advisory board member or consultant for Galderma, LEO Pharma, Lilly, MedImmune, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme, and received speaker honoraria from Chugai, Galderma, LEO Pharma, MedImmune, Pfizer, Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. Corporate sponsorship was provided to the International Eczema Council by AbbVie, Asana, Celgene, Chugai, Dermavant, Dermira, Eli Lilly, Galderma, Leo Pharma, Novartis, Pfizer, Pierre Fabre, Sanofi, Genzyme and Regeneron Pharmaceuticals, Sienna and Valeant. This research was performed independently through the authors’ academic university and hospital affiliations.
ASJC Scopus subject areas
- Infectious Diseases
- Dermatology
